Clinical Trial Update: Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant regimen of tislelizumab, gemcitabine, cisplatin, and S-1 for resectable high-risk cholangiocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• S-1 (tegafur/gimeracil/oteracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Cholangiocarcinoma, Biliary Tract Cancer (BTC) | Phase 2 | Status: NOT_YET_RECRUITING